AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06660628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surface guided radiation therapy
Description: The technology uses modern 3D camera technology to help track and monitor patient movements during set-up and treatment.
Study NCT06660628 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser alignment
Description: Laser systems for virtual simulation and patient positioning in radiotherapy
Study NCT05551559 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bariatric surgery
Description: bariatric surgery
Study NCT06075745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for CMV-MVA Triplex
Description: Arm 2 participants receive two doses of matching placebo CMV-MVA Triplex
Study NCT06476561 — intervention group
Intervention type: OTHER
Intervention: - Sociodemographic Assessment - Psychological Assessment - Quality of Life Assessment - D
Description: The study involves several assessments to evaluate the impact of various factors on dual-task performance in elderly individuals:~1. Sociodemographic Assessment: Collection of data on age, gender, education, income, marital status, and other relevant factors.~2. Psychological Assessment: Use of the Depression Anxiety Stress Scales-21 (DASS-21) to measure levels of depression, anxiety, and stress.~3. Quality of Life Assessment: Utilization of the World Health Organization Quality of Life Brief Form (WHOQOL-BREF) to assess physical health, psychological health, social relationships, and environment.~4. Dual-Task Performance Evaluation: Measurement of the ability to perform a cognitive task (counting backward by threes) simultaneously with a motor task (Nine-Hole Peg Test). The dual-task cost (DTC) is calculated to quantify the impact of cognitive load on motor performance.
Study NCT06104800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorie-restricted diet with red meat
Description: Calorie-restricted diet with macronutrient distribution: 1.5 g/kg of ideal body weight in protein (including red meat), 50% carbohydrates, and 25-30% fats.
Study NCT06104800 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calorie-restricted diet without red meat
Description: Calorie-restricted diet with macronutrient distribution: 1.5 g/kg of ideal body weight in protein (excluding red meat), 50% carbohydrates, and 25-30% fats
Study NCT06470191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B007
Description: B007： Subcutaneous injection was administered on days 1 and 15
Study NCT06470191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin Capsules
Description: Cyclosporin Capsules： Orally, 3.5 mg/kg/d；
Study NCT06388564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Axatilimab will be administered at protocol defined dose.
Study NCT06388564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be administered at protocol defined dose.
Study NCT06388564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Corticosteroids will be administered at protocol defined dose.
Study NCT06254846 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Urine sample, 1st stream
Description: Use of the Colli-Pee® device for collecting the first urine stream
Study NCT06254846 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cervico-vaginal swab
Description: Use of a gold standard reference method = HPV PCR using the Anyplex® II HPV HR kit (Seegene) carried out on a cervico-vaginal swab in ThinPrep® medium (liquid medium medium into which the cervico-vaginal swab is discharged).
Study NCT06660628 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: free breathing
Description: Patients breathe calmly while radiotherapy instead of holding their breath.
Study NCT04769440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mg sulphate
Description: mgso4 infusion will start 15 minutes after intubation , 30 mg/kg LBW of 10%mgso4 in 100 ml normal saline I.V ,over 30 minutes followed by 10 mg/kg LBW for 90 minutes
Study NCT05920356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Oral administration
Study NCT05920356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Intravenous administration
Study NCT06039865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Intervention
Description: Participants will receive customized weekly reports from the pulse oximetry data collected by the consumer wearable.
Study NCT06039865 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist control
Description: Participants only receive usual care from the sleep center.
Study NCT06445985 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrotherapy
Description: Physiotherapy led pool session
Study NCT04997018 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Patients enrolled in this study will undergo ultra-hypofractionated radiation utilizing MR guided, daily online adaptive planning. Patients will receive a standard dose of 8 Gy/fraction for five fractions for a total dose of 40 Gy to the prostate with a simultaneously-delivered boost of 9 Gy for five fractions (clinically non-standard dose of 45 Gy total) to a single dominant lesion with a maximum dimension of at least 0.5 cm, as determined on the pretreatment diagnostic T2 MRI imaging. In the setting of two similarly-sized dominant lesions, both will be boosted.
Study NCT05957432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Black Seed Oil Cap/Tab
Description: possessed anti-H. pylori activity comparable to triple therapy and improved dyspepsia symptoms in infected patients
Study NCT05957432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan, Amoxicillin and Clarithromycin
Description: H pylori vonoprazan based treatment
Study NCT06167343 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL reconstruction
Description: In addition to surgical reconstruction, any structures that may have been injured concomitantly (meniscus, other ligament) will be repaired in the same surgery.
Study NCT05386758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: Four 200 mg capsules administered orally as a single dose
Study NCT05840887 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Knee osteotomy associated with meniscal allograft transplantation
Description: Patients will undergo knee osteotomy associated with meniscal allograft transplantation, which will be implanted by arthroscopic technique with body fixation by all-inside and transosseous sutures to the posterior horn and if necessary to the anterior horn.
Study NCT05840887 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Knee osteotomy
Description: Knee osteotomy
Study NCT03204357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh Autologous whole Blood
Description: Subjects randomized this arm will receive fresh autologous whole blood
Study NCT03204357 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Expectant management of bleeding
Description: the control group that will receive the standard of care expectant management of bleeding and transfusion of allogenic banked blood products
Study NCT04280289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol extract
Description: The test article CBD Cannabis Extract Oral Solution will be manufactured by the University of Mississippi National Center for Natural Products Research (NCNPR) at the Coy Waller Laboratory under FDA Current Good Manufacturing Practices. The drug product, derived from hemp and containing less than 0.3% of Δ9-tetrahydrocannabinol, is no longer a Drug Enforcement Agency (DEA) controlled substance. DEA registrations are not required for the manufacturing, handling or dispensing of these clinical test materials
Study NCT06588647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improving Participation after Stroke Self-Management Program (IPASS)
Description: The IPASS-R program is a group-based self-management intervention that aims to improve problem-solving, action-planning, and resource utilization skills for improved community living and participation. The Activity-Barriers-Changes-Doing-Evaluation (ABCDE) framework is a user friendly problem-solving and goal setting framework that is used repetitively in each session throughout the program. Participants are guided to identify (1) an activity that they want to improve or re-engage in (A); (2) individual and environmental barriers that hinder their engagement (B); (3) changes that they can make to deal with the barriers and improve their engagement (C); and (4) an action plan to pursue (D). After the action plan, participants come back in the next session and evaluate their performance in following through on their plans (E).
Study NCT06588647 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chronic Disease Self-Management Program (CDSMP)
Description: The program is facilitated by two trained leaders in small groups in a community setting with individuals who have chronic health problems and will follow the CDSMP protocol. Participants receive education on various health-related topics applicable to a range of chronic conditions, share experiences, and support one another.
Study NCT05273944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride Liposome Injection
Description: 50mg/m2, intravenous drip on Day 1 of each cycle. On Day 1 of Cycle 1 patients will receive either reference or test product. On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation. To measure pharmacokinetic paratemers of Caelyx® versus Lipodox®.
Study NCT05273944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride Liposome Injection
Description: 50mg/m2, intravenous drip on Day 1 of each cycle. On Day 1 of Cycle 1 patients will receive either reference or test product. On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation. To measure pharmacokinetic paratemers of Caelyx® versus Lipodox®.
Study NCT04896736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multisite tissue oxygenation-guided care
Description: The following intervention algorithm is intended to be used as a guidance only. We emphasize the different aspects that can cause changes in SctO2/SstO2 in a systematic approach. We avoid recommending a concrete drug and method of dosing for a specific condition.~Manage tissue perfusion Preload: overall picture including direct observation of the heart, findings of echocardiography, urine output, blood loss, labs results, HR, BP, PPV, SVV, fluid responsiveness (SV increase >/= 10% following 250 ml fluid bolus) Contractility: direct observation of the heart, findings of echocardiography Stroke volume and heart rate: important determinants of CO Systemic vascular resistance: important determinant of BP Regional vascular resistance: important determinant of tissue perfusion along with perfusion pressure Maintain autoregulation: normalize CO2, avoid potent vasodilators~Manage arterial blood oxygen content~Manage tissue metabolic activity
Study NCT06659107 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closed reduction and fixation by K- wires
Description: Fixation by k-wires with mutual linking technique
Study NCT06661408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group 1
Description: The women assigned to this group will be shown the newborn bath application video prepared by the researchers in groups of 2-4 people in the form of a projection presentation.
Study NCT06661408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group 2
Description: In groups of 2, the researcher will first explain the stages of newborn bathing application by the researcher in the form of a projection presentation, and then the pregnant women will be provided to perform the newborn bathing application on the newborn bathing model and tools simultaneously with the researcher.
Study NCT06657859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLM101
Description: GLM101 IV infusion
Study NCT06607666 — intervention group
Intervention type: DRUG
Intervention: Lanreotide autogel
Description: Identification of clinical, biochemical, molecular markers of response to low and high dose of fg-SRLs
Study NCT06660134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon-like peptide-1 receptor agonists (GLP 1 RA)
Description: In addition to the routine use of Antiarrhythmic Drugs (AADs) and anticoagulants, the strict weight reduction intervention group also uses GLP-1 receptor agonists for glycemic control and weight loss according to guidelines. This group receives a structured weight loss program, regular nutritional advice in accordance with current guidelines, and physical training assistance over a 12-month period. The intervention plan aims for a total weight loss of 10 kilograms while using GLP-1 receptor agonists.
Study NCT06660134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon-like peptide-1 receptor agonists (GLP 1 RA)
Description: In addition to the routine use of Antiarrhythmic Drugs (AADs) and anticoagulants, the strict weight reduction intervention group also uses GLP-1 receptor agonists for glycemic control and weight loss according to guidelines. This group receives a structured weight loss program, regular nutritional advice in accordance with current guidelines, and physical training assistance over a 12-month period. The intervention plan aims for a total weight loss of 10 kilograms while using GLP-1 receptor agonists.
Study NCT06235359 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: intercostal tube
Description: A chest tube is a hollow, flexible tube placed into the chest. It acts as a drain.~Chest tubes drain blood, fluid, or air from around your lungs, heart, or esophagus.~The tube around your lung is placed between your ribs and into the space between the inner lining and the outer lining of your chest cavity. This is called the pleural space. It allows your lungs to fully expand.
Study NCT06454890 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Trop2 CAR-NK cell
Description: chemotherapy followed by Trop2 CAR-NK infusion
Study NCT05867849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabinoid
Study NCT05867849 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive substance
Study NCT06364449 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04831684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be getting placebo for 8 days of dosing.
Study NCT04831684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GET73
Description: Participants will be getting GET73 for 8 days of dosing.
Study NCT04874493 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records
Study NCT04874493 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study NCT05914363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sealed washable floor plus behaviour change
Description: Replacement of rudimentary floors with a cement stabilised floor in all rooms in the dwelling
Study NCT05914363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviour change intervention
Description: Support for behaviour change through 'floor clubs' and the provision of printed guides
Study NCT05914363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine deworming
Description: Treatment of all household members for STH infections (400 mg albendazole in those aged 24 months and above; 200 mg albendazole in those aged 12-23 months)
Study NCT05914363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine deworming
Description: Treatment of all household members for STH infections (400 mg albendazole in those aged 24 months and above; 200 mg albendazole in those aged 12-23 months)
Study NCT05914363 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: treatment for tungiasis
Description: Treatment of tungiasis in those affected by heavy infections (at 0 and 12 months) according to county Department of Health recommendations
Study NCT05914363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: treatment for tungiasis
Description: Treatment of tungiasis in those affected by heavy infections (at 0 and 12 months) according to county Department of Health recommendations
Study NCT05688956 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortimel Advanced, Nutricia
Description: Per 200 mL serving size: 300 kcal, 21 g whey protein, 3 g leucine \& 10 µg Vitamin D.
Study NCT05688956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise programme
Description: Participants will participate in the resistance-based exercise programme twice a week for 12-weeks via Zoom. Each session will last between 45-60 minutes with 2-3 sets and 8-12 reps, twice a week for the 12 weeks.
Study NCT05688956 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise programme
Description: Participants will participate in the resistance-based exercise programme twice a week for 12-weeks via Zoom. Each session will last between 45-60 minutes with 2-3 sets and 8-12 reps, twice a week for the 12 weeks.
Study NCT05688956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary advice
Description: Standard dietary advice to increase intake of protein, leucine and vitamin D using available literature designed for those at risk of malnutrition will be provided to both groups by the research nutritionist. Literature provided will include booklets containing lists of foods high in protein, leucine and vitamin D plus easy-to-prepare meal ideas. The dietary advice provided will be informed by the 24-hour dietary recall information obtained from each participant.
Study NCT05688956 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary advice
Description: Standard dietary advice to increase intake of protein, leucine and vitamin D using available literature designed for those at risk of malnutrition will be provided to both groups by the research nutritionist. Literature provided will include booklets containing lists of foods high in protein, leucine and vitamin D plus easy-to-prepare meal ideas. The dietary advice provided will be informed by the 24-hour dietary recall information obtained from each participant.
Study NCT05845502 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SZ003 CAR-NK
Description: Drug: SZ003 CAR-NK In the escalation study, the minimum initial dose was 5.0×10\^6 cells, then increased to 1.0×10\^8 ,2.0×10\^8 and5.0×10\^8 cells. The infusion is given every 2 weeks.
Study NCT06499090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine 30 MG
Description: patients will receive orally the night before surgery the study medication and daily up to two weeks after Mirtazapine 30 mg tablet
Study NCT06499090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will receive orally the night before surgery the study medication and daily up to two weeks after placebo tablet
Study NCT05915416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Abuse and Neglect Prevention Program
Description: The Child Abuse and Neglect Prevention Program was then revised in line with the opinions and suggestions of the experts. Power-point presentations and training booklet prepared for the final form of this program have been prepared in such a way that the content is exactly the same. Training booklet was distributed to the experiment group after the pre-test and to the control group after the re-test. This booklet is designed as a resource that participants can refer to whenever they need it. Trainings were provided online through the Google Meet application, in a total of four sessions with an average of 30 minutes per session. The contents of the trainings are child neglect, physical abuse, emotional abuse and sexual abuse, respectively. Four different power-point presentations, addressing these sub-dimensions, were prepared for training purposes.
Study NCT05432414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Pomalidomide was administered orally at a dose of 4 mg on days 1-14 of each cycle.
Study NCT05432414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib was administered intravenously or subcutaneously at a dose of 1.3mg/m2 on days 1, 4, 8, 11 of each cycle.
Study NCT05432414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib was administered intravenously or subcutaneously at a dose of 1.3mg/m2 on days 1, 4, 8, 11 of each cycle.
Study NCT05432414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone was administered orally at a dose of 20mg on days the same and next day of bortezomib administration.
Study NCT05432414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone was administered orally at a dose of 20mg on days the same and next day of bortezomib administration.
Study NCT06382727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EN will be continued up to extubation (EN will not be withheld prior to extubation)
Description: As per the arm/group descriptions.
Study NCT05497804 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy
Study NCT05497804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV